Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer

Association of MammaPrint index and 3-year outcome of patients in the FLEX Registry trial with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline

Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care

German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines

Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer

Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens

SWOG S2206 will use MammaPrint® breast cancer recurrence test to examine response to immunotherapy in women with high-risk HR+ breast cancer.

The Dutch National Healthcare Institute (ZIN) has approved MammaPrint® for inclusion in the Dutch National health insurance basic package with immediate effect.

Renowned breast oncologist and clinical researcher to lead ongoing efforts to accelerate diagnostic discoveries and enable precision oncology through real-world evidence-based study platform